Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Breast Cancer Research

Fig. 3

From: Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

Fig. 3

Association between CD4, CD8, and FOXP3 expression and relapse-free interval (RFI). Partial residuals of the multivariable Cox regression models were plotted against the CD4 (a), CD8 (b), and FOXP3 (c) expression. Smoothed lines were drawn based on the spline function of the fitted partial residual values of the Cox regression (RFI; 5 years follow-up) and their standard error range. Vertical gray dashed lines show the threshold used to classify status low and high for each lymphocyte marker, estimated by sensitivity/specificity measurements of differences in RFI. Kaplan-Meier curves and adjusted hazard ratios (HRs) of CD4, CD8, and FOXP3 status were calculated in the whole group (d, e, and f, respectively) and among patients with low-grade tumors (g, h, and i, respectively). Statistical differences between the groups were calculated by the log-rank test (p). Multivariable models were stratified by lymph node status and included the following variables: CD4, CD8, and FOXP3 status; morphology type; tumor grade; tamoxifen arm; tumor size; age at diagnosis; PR; HER2; and PIK3CA mutation status. Abbreviation: HR hazard ratio, CI confidence interval, ER estrogen receptor, RFI relapse-free interval

Back to article page